HER2: a 'predictive factor' ready to use in the daily management of breast cancer patients?

被引：47

作者：

Piccart, MJ ^{[1
]}

Di Leo, A ^{[1
]}

Hamilton, A ^{[1
]}

机构：

[1] Inst Jules Bordet, Unite Chimiotherapie, B-1000 Brussels, Belgium

来源：

EUROPEAN JOURNAL OF CANCER | 2000年 / 36卷 / 14期

关键词：

breast cancer; HER2/receptor tyrosine kinase; chemotherapy; hormonal therapy; prediction of response;

D O I：

10.1016/S0959-8049(00)00162-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The past few years have witnessed an exponential increase in studies trying to identify molecular markers in patients with breast rumours that might predict for the success or failure of hormonal therapy or chemotherapy. HER2, a tyrosine kinase membrane receptor of the epidermal growth factor receptor family. has been the most widely studied marker in this respect. This paper attempts to critically review to what extent HER2 may improve 'treatment individualisation' for the breast cancer patient, (C) 2000 Published by Elsevier Science Ltd.

引用

页码：1755 / 1761

页数：7

共 23 条

[11] GUSTIN MC, 1992, ADV COMP ENV PHYSL, V10, P19
[12] HAMILTON A, 2000, IN PRESS CLIN BREAST
[13] Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
Houston, SJ
Plunkett, TA
Barnes, DM
Smith, P
Rubens, RD
Miles, DW
[J]. BRITISH JOURNAL OF CANCER, 1999, 79 (7-8) : 1220 - 1226
[14] ELEVATED SERUM C-ERBB-2 ANTIGEN LEVELS AND DECREASED RESPONSE TO HORMONE-THERAPY OF BREAST-CANCER
LEITZEL, K
TERAMOTO, Y
KONRAD, K
CHINCHILLI, VM
VOLAS, G
GROSSBERG, H
HARVEY, H
DEMERS, L
LIPTON, A
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) : 1129 - 1135
[15] MENARD S, 1999, P AM SOC CLIN ONCOL, V18, pA9
[16] MUSS H, 1998, P AM SOC CLIN ONCOL, V18, pA68
[17] Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer
Niskanen, E
Blomqvist, C
Franssila, K
Hietanen, P
Wasenius, VM
[J]. BRITISH JOURNAL OF CANCER, 1997, 76 (07) : 917 - 922
[18] erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
Paik, SM
Bryant, J
Park, CH
Fisher, B
Tan-Chiu, E
Hyams, D
Fisher, ER
Lippman, ME
Wickerham, DL
Wolmark, N
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18): : 1361 - 1370
[19] RAVDIN PM, 1998, P AN M AM SOC CLIN, V17, P97
[20] Rozan S, 1998, INT J CANCER, V79, P27, DOI 10.1002/(SICI)1097-0215(19980220)79:1<27::AID-IJC6>3.0.CO

← 1 2 3 →